Trading Review for Cell Therapeutics Incorporated Issued by Beacon Equity

November 2, 2009 6:50 AM EST

DALLAS, Nov. 2, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Cell Therapeutics Incorporated (Nasdaq: CTIC). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The investment report on Cell Therapeutics Inc. (Nasdaq: CTIC) should be of particular interest to biopharmaceutical companies: Abraxis BioSciences Inc. (Nasdaq: ABII), Bristol-Myers Squibb Company (NYSE: BMY) and Eli Lilly & Company (NYSE: LLY).

The report is available at: http://www.beaconequity.com/i/CTIC

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Cell Therapeutics Inc. (CTIC) is a biopharmaceutical company engaged in the development and commercialization of oncology drug therapies for the treatment of cancer. Its portfolio of trial therapies include phase III candidate drug therapy, Pixantrone, for the treatment of non-Hodgkin's lymphoma; phase II drug, Brostallicin, for the treatment of sarcoma; and OPAXIO for the treatment of non-small cell lung, ovarian, and other forms of cancer.

Message Board Search for CTIC: http://www.boardcentral.com/boards/CTIC

In the report, the analyst notes:

"The latest Pixantrone phase II trial results indicate a 70% complete remission rate in patients treated with pixantrone with FPD-R regimen (fludarabine and rituximab); a 47% rate of complete remission in patients treated with CPOP regimen (cyclophosphamide, pixantrone, vincristine, prednisone) for patients that failed CHOP (cycophosphamide, doxorubicin, vincristine, prednisone); and 35% complete remission in a phase III trial in patients treated with pixantrone with rituximab.

"If approved by the U.S. FDA, the market for CTIC's drug candidate Pixantrone could reach more than $1 billion at its market saturation. Brostallicin is the Company's phase II drug candidate for the treatment of sarcoma, with prospects of reaching commercialization at approximately 50% following successful completion of phase II."

To read the entire report visit: http://www.beaconequity.com/i/CTIC

See what investors are saying about these stocks at: http://www.stockhideout.com/

BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

CONTACT: Beacon Equity Research
         Jeff Bishop
         (469)-252-3505
         press@beaconequity.com

Related Categories

Press Releases

Stocks Mentioned

Related Entities

• Twitter

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?